Former Merck president to lead Reliant

Share this article:
Reliant Pharmaceuticals has named former Merck US human health president Bradley Sheares, as its CEO. Sheares, who will also become a member of Reliant’s board of directors succeeds Ernest Mario, who was CEO since 2003. Mario will continue to serve on the board as chairman. While at Merck, Sheares had commercial responsibility for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases in the US. During his tenure as president, Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, operations management and the development and implementation of corporate policies. Sheares served as VP hospital marketing and sales for US human health prior to his promotion to president, US human health in 2001. He joined Merck in 1987 as a research fellow in the Merck Research Laboratories and moved to the US commercial organization in 1990. Reliant is a privately held company based in Liberty Corner, NJ. Reliant’s portfolio consists of primarily cardiovascular-focused products, with a sales and marketing infrastructure comprised of 825 sales representatives nationwide.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.